These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 11821849)

  • 1. Pinpointing anthrax-toxin inhibitors.
    Glick M; Grant GH; Richards WG
    Nat Biotechnol; 2002 Feb; 20(2):118-9. PubMed ID: 11821849
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of phage display and polyvalency to design inhibitors of protein-protein interactions.
    Mourez M; Collier RJ
    Methods Mol Biol; 2004; 261():213-28. PubMed ID: 15064461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexible docking of peptide ligands to proteins.
    Desmet J; De Maeyer M; Spriet J; Lasters I
    Methods Mol Biol; 2000; 143():359-76. PubMed ID: 11084914
    [No Abstract]   [Full Text] [Related]  

  • 4. Interactions between anthrax toxin receptors and protective antigen.
    Scobie HM; Young JA
    Curr Opin Microbiol; 2005 Feb; 8(1):106-12. PubMed ID: 15694864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anthrax protective antigen (PA63) bound conformation of a peptide inhibitor of the binding of lethal factor to PA63: as determined by trNOESY NMR and molecular modeling.
    Hicks RP; Bhattacharjee AK; Koser BW; Traficante DD
    J Med Chem; 2004 Oct; 47(22):5347-55. PubMed ID: 15481973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accounting for ligand-bound metal ions in docking small molecules on adenylyl cyclase toxins.
    Chen D; Menche G; Power TD; Sower L; Peterson JW; Schein CH
    Proteins; 2007 May; 67(3):593-605. PubMed ID: 17311351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carriers versus adapters in stochastic sensing.
    Braha O; Webb J; Gu LQ; Kim K; Bayley H
    Chemphyschem; 2005 May; 6(5):889-92. PubMed ID: 15884071
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular modeling of modified peptides, potent inhibitors of the xWNT8 and hWNT8 proteins.
    Voronkov AE; Baskin II; Palyulin VA; Zefirov NS
    J Mol Graph Model; 2008 Apr; 26(7):1179-87. PubMed ID: 18296089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional characterization of peptide-based anthrax toxin inhibitors.
    Gujraty K; Sadacharan S; Frost M; Poon V; Kane RS; Mogridge J
    Mol Pharm; 2005; 2(5):367-72. PubMed ID: 16196489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raftlike polyvalent inhibitors of the anthrax toxin: modulating inhibitory potency by formation of lipid microdomains.
    Rai PR; Saraph A; Ashton R; Poon V; Mogridge J; Kane RS
    Angew Chem Int Ed Engl; 2007; 46(13):2207-9. PubMed ID: 17310484
    [No Abstract]   [Full Text] [Related]  

  • 11. LRP6 holds the key to the entry of anthrax toxin.
    Bann JG; Cegelski L; Hultgren SJ
    Cell; 2006 Mar; 124(6):1119-21. PubMed ID: 16564002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthrax toxin: the long and winding road that leads to the kill.
    Abrami L; Reig N; van der Goot FG
    Trends Microbiol; 2005 Feb; 13(2):72-8. PubMed ID: 15680766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyvalency: a promising strategy for drug design.
    Vance D; Shah M; Joshi A; Kane RS
    Biotechnol Bioeng; 2008 Oct; 101(3):429-34. PubMed ID: 18727104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stable peptide inhibitors prevent binding of lethal and oedema factors to protective antigen and neutralize anthrax toxin in vivo.
    Pini A; Runci Y; Falciani C; Lelli B; Brunetti J; Pileri S; Fabbrini M; Lozzi L; Ricci C; Bernini A; Tonello F; Dal Molin F; Neri P; Niccolai N; Bracci L
    Biochem J; 2006 Apr; 395(1):157-63. PubMed ID: 16398644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiology. Translocation of anthrax toxin: lord of the rings.
    von Heijne G
    Science; 2005 Jul; 309(5735):709-10. PubMed ID: 16051774
    [No Abstract]   [Full Text] [Related]  

  • 16. Structural prediction of peptides binding to MHC class I molecules.
    Bui HH; Schiewe AJ; von Grafenstein H; Haworth IS
    Proteins; 2006 Apr; 63(1):43-52. PubMed ID: 16447245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanotube-assisted protein deactivation.
    Joshi A; Punyani S; Bale SS; Yang H; Borca-Tasciuc T; Kane RS
    Nat Nanotechnol; 2008 Jan; 3(1):41-5. PubMed ID: 18654449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large-scale structural changes accompany binding of lethal factor to anthrax protective antigen: a cryo-electron microscopic study.
    Ren G; Quispe J; Leppla SH; Mitra AK
    Structure; 2004 Nov; 12(11):2059-66. PubMed ID: 15530370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the proteolytic activity of anthrax lethal factor by aminoglycosides.
    Lee LV; Bower KE; Liang FS; Shi J; Wu D; Sucheck SJ; Vogt PK; Wong CH
    J Am Chem Soc; 2004 Apr; 126(15):4774-5. PubMed ID: 15080670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-association of the transmembrane domain of an anthrax toxin receptor.
    Go MY; Kim S; Partridge AW; Melnyk RA; Rath A; Deber CM; Mogridge J
    J Mol Biol; 2006 Jun; 360(1):145-56. PubMed ID: 16756998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.